secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zura Bio Ltd (ZURA)
CIK:        0001855644
Form:       8-K
Filed at:   2025-05-20T23:59:59+00:00
Accession:  0001104659-25-050715
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zura Bio launches global Phase 2 TibuSHIELD study of tibulizumab in hidradenitis suppurativa
--------------------------------------------------------------------------------

- TibuSHIELD will enroll ~180 adults with moderate-to-severe HS across US, Canada, and Europe.
- Study is 28-week, double-blind, placebo-controlled, with 16-week primary efficacy and 12-week safety follow-up, plus optional OLE.
- Primary endpoint: percent change in total abscess and nodule count at Week 16; secondary endpoints include HiSCR50/75.
- Topline results for primary endpoint expected in Q3 2026.
- Tibulizumab targets both BAFF and IL-17A pathways; still investigational, not FDA-approved.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1855644/000110465925050715/0001104659-25-050715-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1855644/000110465925050715/tm2515452d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-050715

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer